FT. LAUDERDALE, Fla.--(EON: Enhanced Online News)--Puget Technologies (OTCBB: PUGE) announced Cannabis Biotech, its subsidiary, is launching product research for a transmucosal delivery system whereby medical marijuana is delivered through the mucous membrane of the nasal cavity. Part of a larger effort to develop a wider variety of delivery methods to serve a growing, diverse patient base, this project is targeted towards those who desire the benefits of medical marijuana but do not want the harmful effects or stigma of smoking it.
“The multi-billion dollar medical marijuana industry offers excellent growth prospects for Cannabis Biotech which is committed to maintaining strict protocols and quality standards.”
Ken Morrow, prominent international marijuana authority who is heading up the project for Cannabis Biotech said, “This platform will allow for an enhanced therapeutic effect while providing patients with an accurate dosing regimen and a steady rate of delivery across the mucous membrane, avoiding the gastrointestinal tract and loss of a percentage of the medicine through the liver.” He added this product had the potential to replace current similar products in the market which are much less standardized and regulated.
The uptake of medicine via transmucosal systems is well accepted by patients. Flonase (fluticasone propionate) manufactured by GlaxoSmithKline (NYSE: GSK), Rhinocort Aqua (budesonide) by AstraZeneca (NYSE: AZN), and Ortrivine Adult Metered Dose by Novartis (NYSE: NVS) are popular medications which are commonly used in the U.S. to treat hay fever and other allergies. The methodology is used as an anti-influenza therapy and to treat vitamin B deficiency, osteoporosis and nicotine addiction among other conditions.
President and CEO of Puget Technologies Ron Leyland said, “Modern medicine derived from cannabis is coming out of the shadows and a more varied group of patients are expected to seek out its benefits. Cannabis Biotech is poised to deliver scientifically engineered products to meet their needs.” He added, “The multi-billion dollar medical marijuana industry offers excellent growth prospects for Cannabis Biotech which is committed to maintaining strict protocols and quality standards.”
According to one estimate, there are 24.8 million potential patients eligible for medical marijuana in the U.S. (The State of Marijuana Markets 2011).
According to a recent Pew Research report, for the first time in more than 40 years a majority of Americans favor legalization of marijuana use. Currently 20 U.S. states and the District of Columbia have enacted laws to legalize the use of medical marijuana.
CNN Chief Medical Correspondent Dr. Sanjay Gupta recently made global headlines when he changed his mind about cannabis, saying science backs the use of medical marijuana. According to an article based on Gupta’s recent documentary, “WEED,” there are several medical conditions for which patients can use cannabis – cancer, glaucoma, HIV/AIDS, muscle spasms, seizures, severe pain, severe nausea, dramatic weight loss and muscle atrophy.
More information about Cannabis Biotech can be found at http://www.cannabisbiotech.com.
About Puget Technologies (PUGE)
Puget Technologies is a publicly traded company on the OTCBB Market stock exchange under the ticker symbol PUGE. Headquartered in Ft. Lauderdale, Florida, Puget Technologies acquires, develops and sells leading edge consumer oriented products ready for rapid commercialization. Puget plans to become a recognized market leader in its product categories. Much of its resources are dedicated to research and development in order to provide consumers with quality options while meeting the expectations of its investors.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release only speaks as of the date of its distribution.